Temoporfin

Summary

Temoporfin (CHEMBL500576) is an approved small-molecule photosensitizing agent (ATC L01XD05); indicated across 9 conditions including head and neck squamous cell carcinoma and head and neck cancer.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01XD05
• Indications: 9 conditions
• Clinical trials: 8
• Chemistry: 680.7 Da · C44H32N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL500576
Name	Temoporfin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	60751
ChEBI	CHEBI:9437
ATC	L01XD05
Molecular formula	C44H32N4O4
Molecular weight	680.7
InChIKey	LYPFDBRUNKHDGX-UHFFFAOYSA-N

SMILES: C1CC2=NC1=C(C3=CC=C(N3)C(=C4C=CC(=N4)C(=C5C=CC(=C2C6=CC(=CC=C6)O)N5)C7=CC(=CC=C7)O)C8=CC(=CC=C8)O)C9=CC(=CC=C9)O

IUPAC name: 3-[10,15,20-tris(3-hydroxyphenyl)-2,3,22,24-tetrahydroporphyrin-5-yl]phenol

Pharmacological roles (ChEBI): photosensitizing agent.

Also known as: EF-9, EF9, Foscan, M-thpc, Mthpc, SML-1707, SML1707, Temoporfin, Temoporfina, Temoporfine, temoporfin, meta-tetrahydroxy phenylchlorin

Patent coverage: 4,025 distinct patent families (17,074 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
head and neck squamous cell carcinoma	4	MONDO:0010150	EFO:0000181
head and neck cancer	4	MONDO:0005627	EFO:0006859
neoplasm	4	MONDO:0005070	EFO:0000616
squamous cell carcinoma	4	MONDO:0005096	EFO:0000707
head and neck neoplasm	4	MONDO:0005586	EFO:0005950
bile duct carcinoma	2	MONDO:0005496	EFO:0005540
nasopharyngeal carcinoma	2	MONDO:0015459	MONDO:0015459
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060
carcinoma	1	MONDO:0004993	EFO:0000313

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	5
PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003856	PHASE2	UNKNOWN	Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy
NCT01016002	PHASE2	UNKNOWN	Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma
NCT01086488	PHASE2	UNKNOWN	Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma
NCT01415986	PHASE2	TERMINATED	Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers
NCT03003065	PHASE2	COMPLETED	Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers
NCT01637376	PHASE1	WITHDRAWN	Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer
NCT01854684	PHASE1	COMPLETED	Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery
NCT01718223	Not specified	WITHDRAWN	Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).